Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed)

Description

Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed) are isolated from the peripheral blood of newly diagnosed acute myeloid leukemia (AML) patients. The mononuclear cell-rich PBMC layer is separated from diluted whole blood by gradient centrifugation. The cell morphology shows a heterogeneous cell population with a single nucleus, including immature myeloid progenitor cells, monocytes and a small number of lymphocytes.Cytogenetic analysis of these cells commonly reveals chromosomal abnormalities such as t(8;21), inv(16), or monosomy 7, depending on the patient. In in vitro culture, this cell population shows the characteristics of coexistence of adherent growth and suspended growth, and some myeloid progenitor cells can differentiate into leukemic blasts with diverse morphologies These cells typically express CD34, CD33, and HLA-DR, detectable via flow cytometry.They are tumorigenic and can initiate leukemic proliferation when engrafted into immunodeficient mice.

Application

• Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed) can serve as an in vitro cell model to investigate the pathogenesis of de novo AML and developing novel therapeutic strategies. They also provide a platform for investigating immune evasion mechanisms and developing immunotherapies, such as assessing CAR-T/NK cell cytotoxicity and characterizing immune checkpoint expression patterns.